Universidad Peruana Cayetano Heredia
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Schwalb Calderon, Alvaro | |
| dc.contributor.author | Cachay Figueroa, Rodrigo Antonio | |
| dc.contributor.author | Meza, E. | |
| dc.contributor.author | Cáceres Nakiche, Tatiana | |
| dc.contributor.author | Blackman, A. | |
| dc.contributor.author | Maruri, F. | |
| dc.contributor.author | Sterling, T.R. | |
| dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
| dc.date.accessioned | 2021-12-12T20:24:56Z | |
| dc.date.available | 2021-12-12T20:24:56Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/10247 | |
| dc.description.abstract | Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs. Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru | en_US |
| dc.language.iso | eng | |
| dc.publisher | BioMed Central | |
| dc.relation.ispartofseries | BMC Research Notes | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | Drug resistance | en_US |
| dc.subject | Levofloxacin | en_US |
| dc.subject | Moxifloxacin | en_US |
| dc.subject | Ofloxacin | en_US |
| dc.title | Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1186/s13104-021-05832-0 | |
| dc.relation.issn | 1756-0500 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
